Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Conditions
Brief summary
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Detailed description
PRIMARY OBJECTIVE: I. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT. OUTLINE: This is an observational study. Patients undergo blood sample collection and have their medical records reviewed on study. Patients may also optionally undergo ECG on study.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Sponsors
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years of age or older * Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy * One of the following: * Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment * Completed chemotherapy with no cardiotoxicity at least two years post treatment * Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity * An understanding of the protocol and its requirements, risks, and discomforts * The ability and willingness to sign an informed consent
Exclusion criteria
\- Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Collection of biospecimens from patients who developed cardiac toxicity (CRCT) or who are at high risk for developing CRCT | Baseline | Assessed by the number of participants who participate and consent to have their specimen (blood draw) retained for future research. |
Countries
United States
Contacts
CONTACTClinical Trials Referral Office
PRINCIPAL_INVESTIGATORNadine Norton, PhD
Mayo Clinic
Outcome results
None listed